Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: extended release dipyridamole 200mg/aspirin 25mg
DRUG: 81mg aspirin

Sponsor

Oklahoma Medical Research Foundation